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C/EBPa Expression Is Downregulated in Human
Nonmelanoma Skin Cancers and Inactivation of
C/EBPa Confers Susceptibility to UVB-Induced Skin
Squamous Cell Carcinomas
Elizabeth A. Thompson1, Songyun Zhu1, Jonathan R. Hall1, John S. House1, Rakesh Ranjan1, Jeanne A. Burr1,
Yu-Ying He2, David M. Owens3,4 and Robert C. Smart1
Human epidermis is routinely subjected to DNA damage induced by UVB solar radiation. Cell culture studies
have revealed an unexpected role for C/EBPa (CCAAT/enhancer-binding protein-a) in the DNA damage
response network, where C/EBPa is induced following UVB DNA damage, regulates the G1 checkpoint, and
diminished or ablated expression of C/EBPa results in G1 checkpoint failure. In the current study we observed
that C/EBPa is induced in normal human epidermal keratinocytes and in the epidermis of human subjects
exposed to UVB radiation. The analysis of human skin precancerous and cancerous lesions (47 cases) for C/EBPa
expression was conducted. Actinic keratoses, a precancerous benign skin growth and precursor to squamous
cell carcinoma (SCC), expressed levels of C/EBPa similar to normal epidermis. Strikingly, all invasive SCCs no
longer expressed detectable levels of C/EBPa. To determine the significance of C/EBPa in UVB-induced skin
cancer, SKH-1 mice lacking epidermal C/EBPa (CKOa) were exposed to UVB. CKOamice were highly susceptible
to UVB-induced SCCs and exhibited accelerated tumor progression. CKOa mice displayed keratinocyte cell
cycle checkpoint failure in vivo in response to UVB that was characterized by abnormal entry of keratinocytes
into S phase. Our results demonstrate that C/EBPa is silenced in human SCC and loss of C/EBPa confers
susceptibility to UVB-induced skin SCCs involving defective cell cycle arrest in response to UVB.
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INTRODUCTION
The epidermis is routinely subject to DNA damage by UVB,
which is considered to be the principal carcinogenic
component of sunlight. Exposure to UVB results in DNA
damage in the form of cyclobutane pyrimidine dimers, 6–4
photoproducts, DNA strand breaks, and DNA crosslinks
(Brash, 1997; de Gruijl et al., 2001). If not repaired or if
misrepaired, this DNA damage can result in mutations in the
genome, and can ultimately contribute to the development of
skin cancers (Brash et al., 1991). Solar radiation is responsible
for 41,000,000 nonmelanoma skin cancer cases per year in
the United States, and these cases account for 40% of all new
cancer cases diagnosed each year in the United States
(American Cancer Society, 2008).
To maintain genome integrity and to prevent heritable
mutations that lead to cancer, cells respond to DNA damage
produced by intrinsic or environmental factors by engaging
the DNA damage response (DDR) network. This network
entails signaling pathways involving cell cycle checkpoints,
DNA repair, transcription programs, and apoptosis. Cell
cycle checkpoints can occur in any phase of the cell cycle
and are characterized as a pause in the cell cycle that allows
time for the repair of damaged DNA. Defective checkpoints
can contribute to genome instability and cancer pathogenesis
(Kastan and Bartek, 2004).
C/EBPa (CCAAT/enhancer-binding protein-a) is one of the
six members of the C/EBP family of basic leucine zipper
transcription factors (Ramji and Foka, 2002; Johnson, 2005).
C/EBPa has been established as a tumor-suppressor gene in
human acute myeloid leukemia (Pabst et al., 2001).
Additionally, there is circumstantial evidence for its
function as a tumor suppressor based on diminished C/EBPa
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expression in a multitude of human tumor types including
liver (Xu et al., 2001), lung (Halmos et al., 2002), breast
(Gery et al., 2005), endometrial (Takai et al., 2005), and head
and neck squamous cell carcinomas (SCCs; Bennett et al.,
2007). The traditional view of C/EBPa in cell biology
involves its role in cellular differentiation and metabolism
(Roesler, 2001); in cancer, the traditional view holds that it
has a tumor-suppressor role, where the loss of expression/
function results in an impaired differentiation commitment
accompanied by deregulated proliferation (Schuster and
Porse, 2006; Koschmieder et al., 2009). However, recent
studies indicate that the role of C/EBPa in cells/cancer is
more complex and multifaceted than originally thought
(Yoon and Smart, 2004; Loomis et al., 2007; Ranjan et al.,
2009). Cell culture studies have revealed an unexpected role
for C/EBPa in the DDR in keratinocytes where C/EBPa is
induced following UVB-induced DNA damage, and it
regulates the G1 checkpoint. Diminished or ablated expres-
sion of C/EBPa results in G1 checkpoint failure following
UVB-induced DNA damage (Yoon and Smart, 2004; Ranjan
et al., 2009). In further support of a nonparadigmatic C/EBPa
tumor-suppressor function, mice lacking C/EBPa in their
epidermis do not display alterations in differentiation or
proliferation and are susceptible to chemical carcinogen-
induced skin tumorigenesis (Loomis et al., 2007).
Given the function of C/EBPa as a mediator of the G1
checkpoint in keratinocytes in response to UVB, it is possible
that C/EBPa functions as a suppressor of UVB-induced
tumorigenesis. Whereas C/EBPa expression is diminished in
mouse skin SCCs (Oh and Smart, 1998; Shim et al., 2005),
C/EBPa levels have not been examined in human skin
precancerous and cancerous lesions. Therefore, the objec-
tives of this study were: to examine the expression of C/EBPa
in human skin precancerous and cancerous lesions, to
characterize the response of C/EBPa to UVB in human
keratinocytes and human skin; and to develop an in vivo
SKH-1 mouse model to determine the in vivo physiological
significance of C/EBPa in UVB-induced skin tumorigenesis.
RESULTS
C/EBPa expression is ablated in human skin SCCs but not in
precancerous actinic keratoses
We examined the expression of C/EBPa in normal human
epidermis, precancerous actinic keratoses, keratoacantho-
mas, SCCs in situ, and invasive SCCs as well as basal cell
carcinomas. Immunohistochemical (IHC) staining for C/EBPa
in human skin showed that C/EBPa was extensively expressed
in the nuclei of nondividing keratinocytes of the suprabasal
layers of the epidermis (Figure 1a). C/EBPa expression was
also detected, although less frequently, in keratinocytes in the
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Figure 1. C/EBPa (CCAAT/enhancer-binding protein-a) expression in human skin and precancerous and cancerous lesions. (a) Immunohistochemical (IHC)
staining for C/EBPa expression was conducted on 47 individual cases. (b) Expression was scored according to the following: (þ þ þ ) intense nuclear staining in
430% of keratinocytes, (þ þ ) moderate nuclear staining in 10–30% of keratinocytes, (þ ) weak nuclear staining in o10% of keratinocytes, and () no
detectable nuclear staining. Scale bar¼ 20 mm.
1340 Journal of Investigative Dermatology (2011), Volume 131
EA Thompson et al.
C/EBPa, Cell Cycle Arrest, and UVB Skin Tumorigenesis
proliferative basal layer of epidermis. Actinic keratoses, a
precancerous benign skin growth of which a small percen-
tage progress to SCC, expressed levels of C/EBPa similar to
normal epidermis (Figure 1a and b). Keratoacanthomas, once
considered as terminally benign but now regarded and
treated by many dermatologists as a malignant growth that
can progress to SCC, expressed reduced levels of C/EBPa with
20% of keratoacanthomas no longer expressing detectable
levels of C/EBPa (Figure 1a and b). Most striking, however,
were the SCCs where the majority of both SCCs in situ (80%)
and invasive SCCs (100%) no longer expressed detectable
levels of C/EBPa (Figure 1a and b). Similarly, the IHC staining
for C/EBPa was absent in 14/16 basal cell carcinoma cases
(data not shown).
C/EBPa is induced in human skin in vivo in response to UVB
Most human nonmelanoma skin cancers are caused by solar
radiation, and UVB radiation is considered the most
carcinogenic component of sunlight. To characterize the
effects of UVB exposure on the expression of C/EBPa in
human keratinocytes, we exposed subconfluent proliferating
normal human epidermal keratinocytes to 5, 10, or
15mJ cm2 UVB. Immunoblot analysis for C/EBPa revealed
that the expression of C/EBPa protein was induced at all
doses (Figure 2a). To characterize the effects of UVB
exposure on the expression of C/EBPa in human skin
in vivo, biopsies from UVB-treated human skin (1 minimum
erythemic dose (MED) UVB) (N¼ 5) were compared with
biopsies from non-sun-exposed human skin (N¼5) for
C/EBPa expression. C/EBPa levels were increased throughout
the epidermis of UVB-treated human skin as determined by
the increased C/EBPa IHC nuclear staining intensity as well as
by the overall statistically significant increase in the number
of keratinocytes staining positively for C/EBPa (Figure 2b–d
and Supplementary Figure S1 online). Although UVB treat-
ment increased the percentage of C/EBPa-expressing kerati-
nocytes in the spinous and granular nondividing suprabasal
layers by 2.3-fold, we observed a 4.3-fold increase in
the number of basal keratinocytes expressing C/EBPa
(Figure 2b–d).
Similar to human skin, SKH-1 hairless mouse skin responds to
UVB with the induction of C/EBPa
We treated SKH-1 hairless mice, a well-characterized mouse
model frequently utilized to study the effects of UVB in skin
in vivo (Benavides et al., 2009), with UVB (50mJ cm2) and,
similar to human skin, we observed a significant increase in
C/EBPa-expressing keratinocytes in the suprabasal and basal
proliferative compartments of epidermis (Figure 3a). There
was an B2-fold increase in the number of C/EBPa positively
stained suprabasal cells, and a 3-fold increase in the number
of C/EBPa positively stained basal keratinocytes (Figure 3b).
To begin to determine the physiological significance of UVB-
induced epidermal C/EBPa in vivo, we generated an
epidermal-specific C/EBPa knockout SKH-1 mouse, hereafter
referred to as conditional knockout (CKOa). CKOamice were
generated from C/EBPafl/fl SKH-1 mice and keratin 5 (K5) Cre
(K5Cre) SKH-1 mice where the K5 promoter directs Cre
recombinase expression to the epidermis and other stratified
squamous epithelia. As shown in Figure 3c, C/EBPa protein
was not detectable in epidermal protein extracts prepared
from CKOa mice. CKOa mice did not display any abnormal
gross or morphological skin phenotype (data not shown).
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Figure 2. C/EBPa (CCAAT/enhancer-binding protein-a) is induced by UVB
in human skin in vivo. (a) Immunoblot analysis of cell lysates from primary
human epidermal keratinocytes. (b) Immunohistochemical (IHC) staining for
C/EBPa in sections from untreated and UVB-treated human skin. Human skin
biopsies were collected 24hours after UVB treatment (1 minimum erythemic
dose (MED)). (c) C/EBPa-positive staining basal cells in UVB-treated human
skin. (d) Percentage of C/EBPa IHC-positive keratinocytes in untreated and
UVB-treated human skin. An average of 360 and 400 basal cells and
suprabasal cells, respectively, were counted per biopsy. Data are expressed as
the mean±SE (N¼ 5 individuals per treatment group). *Significantly different
from untreated controls, Po0.025, Student’s t-test. Black arrows indicate
C/EBPa-positive basal keratinocytes; dashed line indicates basement
membrane. Scale bar¼10 mm.
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Loss of C/EBPa results in increased susceptibility to
UVB-induced skin tumorigenesis
The most susceptible human population to UVB-induced
damage is classified as type 1 according to the Fitzpatrick
Classification Scale. These individuals have very fair and
often freckled skin, have blond or red hair, always sun burn,
and are highly susceptible to solar radiation-induced
nonmelanoma skin cancer. The MED of UVB for this
susceptible population is B20–25mJ cm2. Therefore, we
exposed CKOa and K5Cre control mice to 20mJ cm2 UVB
three times weekly to test whether the loss of C/EBPa in skin
keratinocytes confers susceptibility to UVB-induced tumor-
igenesis. As shown in Figure 4a and b, CKOa mice were
highly susceptibility to UVB-induced skin tumorigenesis as
evidenced by decreased latency (18 weeks), increased tumor
incidence (85 vs. 25%), and a 6-fold increase in tumor
multiplicity. Histological analysis of all skin tumors at the
termination of experiment revealed that the majority of
tumors (B90%) in both genotypes were SCCs (in situ or
invasive). Most importantly, we observed that 48% of SCCs in
CKOa mice were invasive SCCs compared with 15% in the
UVB-treated K5Cre control mice (Figure 4c). Invasive
carcinomas were identified by severe dysplasia to anaplastic
growth, marked atypia in all cell layers, and most impor-
tantly, invasion through the panniculus carnosus and/or
basement membrane (Supplementary Figure S2 online). To
demonstrate that these tumors were the result of UVB
treatment and not advanced age, 8 CKOa mice were held
for 52 weeks and no skin tumors of any kind were detected.
Collectively, these results indicate that loss of C/EBPa confers
susceptibility to UVB-induced skin cancer at a biologically
relevant dose and loss of C/EBPa accelerates skin tumor
progression.
C/EBPa has a role in UVB-induced inhibition of cell cycle
progression in vivo
To determine whether the ablation of epidermal C/EBPa
alters the ability of keratinocytes to undergo a cell cycle arrest
in response to UVB treatment in vivo in mouse skin, we
treated K5Cre control mice and CKOa mice with UVB, and
then examined the number of actively replicating keratino-
cytes post-UVB by measuring the incorporation of the
nucleotide analog BrdU (1 hour BrdU pulse before skin
collection). As shown in Figure 5a, UVB-treated control mice
(K5Cre) displayed a significant cell cycle arrest; at 4 hours
post-UVB treatment, there was B60% decrease in the
number of BrdU-positive S-phase basal keratinocytes in the
epidermis and this decrease was sustained at 6 and 10 hours
post-UVB (Figure 5a). At 12 hours post-UVB, the number of
BrdU-positive S-phase basal keratinocytes returned to un-
treated control levels (data not shown). Although UVB-
treated CKOa mice displayed a similar cell cycle arrest as
UVB-treated control mice at 4 hours post-UVB treatment, this
inhibition was not sustained and cells resumed their
progression in the cell cycle prematurely. At 6 hours post-
UVB, the number of BrdU-positive S-phase cells was
significantly increased and by 10 hours post-UVB treatment,
there was a 3-fold increase in BrdU-positive S-phase basal
keratinocytes in CKOa epidermis compared with UVB-
treated control mice. Representative examples of BrdU-
positive S-phase staining at 10 hours post-UVB in K5Cre
and CKOa mouse epidermis are shown in Figure 5a (right
panel). These results indicate that the loss of C/EBPa in
epidermis results in an impaired cell cycle arrest in response
to UVB in vivo.
To further investigate the role of C/EBPa in UVB-induced
cell cycle checkpoints in epidermis in vivo, we utilized an
in vivo model of cell cycle regulation involving the induction
of synchronous cell proliferation induced by the potent
mitogen, 12-O-tetradecanoylphorbol-13-acetate (TPA) (Foley
et al., 1993; Kim et al., 1997; Rodriguez-Puebla et al., 1998).
A single topical treatment of TPA resulted in synchronous
entry of G1 keratinocytes into S phase as determined by
BrdU-positive basal cells at 12 hours post-TPA treatment and
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Figure 3. C/EBPa (CCAAT/enhancer-binding protein-a) is induced by UVB
in SKH-1 mouse skin in vivo and is ablated in the epidermis of SKH-1 CKOa
mice. (a) Immunohistochemical (IHC) staining for C/EBPa in untreated and
UVB-treated mouse skin, and C/EBPa-positive basal cells in UVB-treated
mouse skin. (b) C/EBPa IHC-positive keratinocytes in untreated and UVB-
treated mouse skin. Data are expressed as the mean number of C/EBPa-
positive keratinocytes per cm length of skin±SE (N¼3 mice per group). A cm
of SKH-1 skin contains 978±76 basal cells and X2 cm were counted per
mouse. (c) Immunoblot analysis of epidermal lysates from wild-type (WT),
keratin 5 Cre (K5Cre), and CKOamice. Black arrows indicate C/EBPa-positive
basal cells; scale bars¼10 mm. *Significantly different from untreated
controls, Po0.05, Student’s t-test.
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S-phase cells further increased at 14 and 16 hours in control
mice (1 hour BrdU pulse before skin collection; Figure 5b).
TPA-treated CKOa mice responded similarly and the
numbers of S-phase cells were not significantly different
from TPA-treated control mice at all time points (P40.3, data
not shown). To determine the effect of UVB on this entry into
S phase, K5Cre and CKOa mice were treated with TPA, and
4 hours later, a time when keratinocytes are still in G1, were
either treated with UVB (50mJ cm2) or left untreated. The
number of BrdU-positive S-phase cells were then determined
at 14 hours post-TPA treatment and 10 hours post-UVB. As
shown in Figure 5c, TPA-treated K5Cre and CKOa mice not
exposed to UVB displayed a 3-fold increase in the number of
BrdU-positive S-phase keratinocytes. UVB treatment of TPA-
treated mice resulted in dramatic decreases in the number of
BrdU-positive S-phase cells in the epidermis of both
genotypes compared with TPA treatment alone (Figure 5c).
However, CKOa mice displayed B3 times more BrdU-
positive S-phase cells than similarly treated K5Cre mice.
Collectively, our findings suggest that the loss of epidermal C/
EBPa results in an impaired cell cycle arrest involving the G1-
to S-phase transition in response to UVB in vivo in mouse
epidermis.
Because p53 is an important player in the DDR and a key
mediator of checkpoints following DNA damage, we wanted
to determine whether the impaired cell cycle arrest at the G1-
to S-phase transition observed in the CKOa mice following
UVB treatment could be related to deficiencies in p53. We
performed immunoblot analysis for p53 on epidermal lysates
from both UVB-treated (50mJ cm2) and untreated K5Cre and
CKOa mice, and observed an induction in p53 protein in
both genotypes following UVB treatment (Figure 5d). To
further determine whether p53 was induced to a similar
extent in both genotypes, IHC staining and quantitation of
p53-positive basal cells were performed, and no statistically
significant differences were found (Figure 5d).
DISCUSSION
C/EBPa is abundantly expressed in the mouse and human
epidermis (Swart et al., 1997; Maytin and Habener, 1998; Oh
and Smart, 1998) and in this study we report that C/EBPa is
induced by UVB in human epidermal keratinocytes and
human epidermis. Analysis of C/EBPa expression in human
skin and human skin precancerous and cancerous lesions
revealed that C/EBPa expression is downregulated in SCCs in
situ and in invasive SCCs and that expression of C/EBPa is
normal in actinic keratoses. These results indicate that loss of
C/EBPa expression is not an early event in SCC development
but occurs during progression from actinic keratoses to
invasive SCCs. The mechanism through which C/EBPa is
downregulated in human and mouse SCCs is unknown;
however, promoter hypermethylation is a candidate as C/
EBPa promoter hypermethylation has been shown to be
important in the decreased expression of C/EBPa in breast
cancer as well as head and neck cancers (Gery et al., 2005;
Bennett et al., 2007).
p53 is frequently mutated in human skin cancer and this is
an early essential event (Brash, 1997). Although actinic
keratoses are the precursor lesion to SCCs, only a small
percentage of actinic keratoses (1–10%) actually progress to
SCCs, even though both actinic keratoses and SCCs share a
high frequency (70%) of mutant p53 and similar p53
mutation spectra (Callen et al., 1997; Ortonne, 2002;
Giglia-Mari and Sarasin, 2003; Stockfleth and Kerl, 2006).
These results indicate that mutant p53 is not sufficient for the
progression of actinic keratoses to SCCs and that additional
events are required for actinic keratosis progression. One
such event may be the loss of C/EBPa, as C/EBPa expression
is retained in actinic keratoses, but C/EBPa expression is
silenced in SCCs. These results suggest that loss of C/EBPa
expression may be a critical event in the progression of
precancerous actinic keratoses to invasive SCCs. Our current
results in CKOamice demonstrate that the ablation of C/EBPa
in mouse epidermis confers susceptibility to UVB-induced
SCCs at a biologically relevant dose and results in the
acceleration of skin cancer progression to invasive SCCs.
Additionally, earlier studies showed that mice lacking C/EBPa
in their epidermis are also more susceptible to chemical
carcinogen-induced skin tumorigenesis, and tumors that
develop in these mice exhibited an accelerated rate of
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malignant progression to invasive SCCs (Loomis et al., 2007).
Collectively, these results indicate an important role for the
loss of C/EBPa in skin cancer progression induced by UVB
radiation or chemical carcinogens.
The recent comprehensive genomic characterization of
human cancers has revealed that genomic instability is a
common characteristic of cancer, that human cancer cells
contain hundreds if not thousands of mutations, and that the
mutation rate in cancer cells greatly exceeds that in normal
cells (Lengauer et al., 1998; Bielas et al., 2006; Cancer
Genome Atlas Research Network, 2008; Ding et al., 2008;
Nancarrow et al., 2008). It is the accumulation of genome
alterations in critical genes over time that drives the cancer
process. There is substantial evidence for a mutator pheno-
type in cancer in which the mutation rate in cancer cells is
much greater than in normal cells, resulting in increases in
random and clonal somatic mutations (Bielas and Loeb,
2005; Bielas et al., 2006; Loeb et al., 2008). Studies in
genetically engineered mice and keratinocytes in culture
have revealed a critical role for C/EBPa in the DDR network
where following DNA damage, C/EBPa is highly induced and
has a critical role in the G1-cell cycle checkpoint (Yoon and
Smart, 2004; Ranjan et al., 2009). The genetic ablation or
knockdown of C/EBPa in keratinocytes results in G1
checkpoint failure in which cells inappropriately enter S
phase following UVB-induced DNA damage (Yoon and
Smart, 2004; Ranjan et al., 2009). In this study, we report
in vivo experiments in which mice lacking C/EBPa expression
in their epidermis display an impaired cell cycle arrest in
response to UVB treatment. Treatment with the potent
mitogenic phorbol ester, TPA, allowed us to induce a highly
synchronous entry of G1 keratinocytes into S phase in vivo in
mouse epidermis. Results from treatment of mice with both
TPA and UVB support a role for C/EBPa in the G1 checkpoint
in response to UVB-induced DNA damage in vivo. Defective
checkpoints can contribute to genome instability and cancer
(Kastan and Bartek, 2004) and we suggest that the loss of
C/EBPa expression in keratinocytes contributes to accumula-
tion of UVB-induced mutations (genomic instability/mutator
phenotype) and the acceleration of skin cancer progression
through G1 checkpoint failure.
Although a definitive functional role for C/EBPa in the G1
checkpoint in the DDR has been identified, the molecular
mechanism through which C/EBPa regulates the G1 check-
point following DNA damage is completely unknown.
Although several mechanisms have been proposed as to
how C/EBPa inhibits cell cycle progression, none involve the
G1 checkpoint and DDR. Most proposed mechanisms were
derived from forced expression studies (Johnson, 2005) and
many of the proposed mechanisms have been refuted in the
literature and all remain controversial (Johnson, 2005). Future
studies will be aimed at the elucidation of the molecular
mechanism through which C/EBPa regulates the cell cycle
progression in response to DNA damage.
MATERIALS AND METHODS
Mice
To generate K5Cre;C/EBPafl/fl SKH-1 mice, K5Cre;C/EBPafl/fl
(C57Bl6/129SV) male (Lee et al., 1997; Ramirez et al., 2004;
Loomis et al., 2007) mice were mated to SKH-1 (Charles River Labs,
Wilmington, MA) females. Male K5Cre;C/EBPafl/ males were
backcrossed to SKH-1 females 5 times to obtain SKH-1 K5Cre and
K5Cre;C/EBPafl/fl littermates that were used in this study. Mice were
genotyped for K5Cre and C/EBPafl/fl using PCR (Lee et al., 1997;
Ramirez et al., 2004) and tail DNA. All aspects of animal care and
experimentation described in this study were conducted according
to the National Institutes of Health guidelines and approved by the
Institutional Animal Care and Use Committee of the North Carolina
State University.
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before killing. Data are expressed as BrdU-positive cells per cm length of
skin±SE. NX3/genotype/treatment. (a) Mice were treated with UVB.
#Different from untreated mice of the same genotype, Po0.05; *not different
from untreated mice of the same genotype, P40.05. Photomicrographs of
BrdU staining. Scale bar¼ 10mm. (b) TPA (12-O-tetradecanoylphorbol-13-
acetate) treatment causes keratinocytes to enter S phase. (c) Mice were treated
with TPA and 4hours later, mice were either treated with UVB or not and they
were killed at 14 hours post-TPA. *Different CKOa TPA/UVB versus keratin 5
Cre (K5Cre) TPA/UVB, Po0.05. (d) Immunoblot analysis of epidermal lysates
before and after UVB treatment. The right panel shows p53
immunohistochemical (IHC)-positive basal keratinocytes in mouse
skin±UVB.
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Cell culture
Normal human epidermal keratinocyte cells (Cambrex, East Ruther-
ford, NJ) were cultured in KGM keratinocyte medium (Lanza,
Walkersville, MD). For UVB treatment, cells were treated as reported
in Yoon and Smart (2004). The UVB lamp (model EB 280C;
Spectronics, Westbury, NY) utilized emits wavelengths between 280
and 350nm with a spectral peak at 312 nm.
Human cutaneous precancerous and cancerous lesions
Human specimens were obtained from de-identified patients seen at
the University of Chicago under approval of the IRB (Institutional
Review Board) and in accordance with the Declaration of Helsinki
Principles. Tissues were formalin fixed and sections from paraffin-
embedded blocks were diagnosed by dermatopathogists.
Human skin and UVB treatment
Skin biopsies were obtained from a single-center, double-blind,
randomized phase II study, which assessed UV-induced erythema
and cutaneous carcinogenesis, as assessed through surrogate
biological markers in biopsied skin after exposure of skin in normal
volunteers aged 20–60 years with Fitzpatrick type, I, II, III, and IV
skin to UV radiation from artificial light sources. Biopsy specimens
from UV-irradiated sites from five individuals with Fitzpatrick type II
skin were analyzed in this study. The MED for each volunteer was
determined by applying graded doses of UVB (10–80mJ cm2) to the
back with a solar stimulator (Solar Light Company, Philadelphia PA,
Model XPS 200, PMA 2100). The solar simulator UV irradiation of
subjects was conducted at the Clinical Pharmacology Unit of the
Department of Dermatology at the Health Sciences Campus of
Columbia University, College of Physicians and Surgeons under the
approved IRB protocol (IRB no. AAAA3102), and in accordance with
the Declaration of Helsinki Principles. Written, informed consent
was obtained from all patients. The erythema response was read after
24 hours and the MED was defined as the least amount of energy that
produces uniform perceptible redness completely filling the test site.
Biopsies were obtained using standard surgical technique, anesthe-
sia with 1% lidocaine with or without epinephrine. Biopsies were
embedded in optimal cutting temperature medium and frozen in
liquid nitrogen-cooled isopentane. Frozen slides containing histolo-
gical sections of non-sun-exposed normal skin specimens were
kindly provided by Dr Uffe Birk Jensen (University of Aarhus,
Denmark).
Mouse UVB treatments
For cell cycle studies, mice were treated with a single 50mJ cm2
UVB treatment. The UVB lamp utilized emits wavelengths between
290 and 350nm with a spectral peak at 312 nm (UVP, Upland, CA).
For TPA studies, a single topical application of 5 nmol TPA (LC
Laboratories, Woburn, MA) in 100 ml acetone was applied dorsally.
For UVB-tumorigenesis studies, 8–10-week-old mice were treated
with 20mJ cm2 UVB three times weekly. Histological criteria for the
classification of tumors were conducted according to Thomas-Ahner
et al. (2007) and Benavides et al. (2009). SCCs were classified as
invasive if the carcinoma cells invaded the panniculus carnosus or
the basement membrane into the dermis. SCC in situ displayed the
histological features of the invasive SCCs but remained confined to
the epidermis. All SCCs displayed severe dysplasia to anaplastic
growth, marked atypia in all cell layers, high heterogeneity in cell
morphology, increased number of mitoses, and increased nuclear/
cytoplasm ratio.
IHC staining
Sections of human skin were prepared for staining as follows: frozen
sections of human skin from individuals exposed to UVB or not were
air dried for 30minutes, fixed in acetone for 5minutes, and washed
in phosphate-buffered saline (PBS) containing 0.1% Tween-20.
Formalin-fixed and paraffin-embedded sections of human skin,
actinic keratoses, keratoacanthomas, SCCs in situ, and invasive SCCs
were deparaffinized, treated with 3% H2O2 followed by 0.1%
Triton-X100, and antigen retrieval was conducted using 1 R-Buffer
A in 2100 Retriever (Electron Microscopy Sciences, Hatfield, PA).
After rinsing in PBS, sections were incubated with 3% H2O2, and
blocked with 3% normal rabbit serum for 30minutes at room
temperature. Human skin tissue arrays purchased from Biomax,
Rockville, MD (SK-481t, SK-482t, US Biomax) were deparaffinized,
treated with 3% H2O2, and antigen retrieval was performed by
autoclaving (120 1C for 15minutes at 15 lbs of pressure) in citrate
buffer. Frozen sections, formalin-fixed sections, and tissue arrays
were all incubated overnight at 4 1C with either a 1:250 dilution
(frozen sections and tissue arrays) or a 1:500 dilution of C/EBPa
(SC9314; Santa Cruz, Santa Cruz, CA) antibody. Paraffin-embedded
sections of mouse skin stained for p53 were incubated with a 1:500
dilution (SC6243; Santa Cruz). Slides were then incubated with
biotinylated anti-goat IgG (Vector Laboratories, Burlingame, CA) for
30minutes. Detection was made with the ABC kit (Vector
Laboratories) and 3,30-diaminobenzidine (Biogenex, Fremont, CA)
as the chromagen. IHC staining in mouse skin histological sections
for C/EBPa was performed as described (Yoon and Smart, 2004).
Preparation of protein lysates
The epidermal layer from isolated skin was removed by scraping using
a surgical scalpel. Recovered epidermis was then placed in RIPA buffer
(1% IGEPAL, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate), with the following added fresh before use; 1mM dithiothreitol,
1mM sodium orthovanadate, 1mM phenylmethylsulfonyl fluoride, and
1 protease inhibitor cocktail (Roche, Indianapolis, IN) in PBS. Lysates
were sonicated and centrifuged as mentioned below (cells in culture).
Normal human epidermal keratinocyte cells were washed with cold
PBS, followed by scraping and centrifugation. Cells were then
resuspended in RIPA buffer as described above for epidermis. Following
sonication, cell lysates were centrifuged at 14,000 g for 10minutes,
and supernatants were collected and stored at 80 1C.
Immunoblot analysis
Whole cell lysates were subjected to electrophoresis on 12% Tris
glycine gels. Proteins were transferred to a polyvinylidene fluoride
membrane, incubated in blocking buffer, and probed for human
C/EBPa 1:1,000 (C/EBPa pAB; Active Motif, Carlsbad, CA), a-tubulin
1:2,000 (sc-8035; Santa Cruz), b-actin 1:10,000 (A-5441; Sigma,
St Louis, MO), or p53 1:2,000 (SC6243, Santa Cruz). Membranes were
washed, and probed with horseradish peroxidase-linked secondary
antibody 1:2500 (NA934V; GE Healthcare, Piscataway, NJ).
Cell proliferation
Mice were injected intraperitoneally with BrdU (B5002, Sigma)
(100mgkg–1 of BrdU in PBS) and killed 1hour later. The epidermis
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was collected and formalin-fixed paraffin-embedded sections were
subjected to IHC staining for BrdU as described (Loomis et al., 2007).
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